Mild cognitive impairment (MCI) is a heterogeneous state between normal ageing and early dementia. It has been referred to as an objective cognitive complaint for age, in a person with essentially normal functional activities, who does not have dementia.1 It affects 19% of people aged 65 and over.2 Around 46% of people with MCI develop dementia within 3 years compared with 3% of the population of the same age.3 Petersen distinguishes subtypes, depending on whether single or multiple cognitive domains are affected, and whether there is a predominant memory complaint. Amnestic MCI, in which memory is affected, more often progresses to Alzheimer’s disease, whereas MCI affecting a single non-memory domain may herald a separately analysed subgroup had MCI.

The number of individuals diagnosed with MCI is growing in Western countries as people are encouraged to present early with memory problems to avoid crisis, but we know little about how to reduce deterioration. The UK National Institute for Health and Care Excellence (NICE) recommends follow-up to ensure dementia is diagnosed and care planned at an early stage, but does not mention specific treatments.4 Form et al.5 calculated that dementia prevalence would be halved if its onset were delayed for 5 years. Neuroprotection, treating vascular risk factors or increasing cognitive reserves could theoretically delay dementia, and could be targeted at people with MCI who are at a particularly high risk of developing it. Previous reviews have focused on specific treatments for MCI. Systematic reviews of randomised controlled trials (RCTs) of all cholinesterase inhibitors,6 donepezil7 and galantamine8 concluded that there are marginal beneficial effects that are outweighed by the risks of adverse events, including an unexplained increased mortality rate with galantamine. A 2009 Cochrane review found that memory training (specific neuropsychological exercises to improve memory) improved immediate and delayed verbal recall in people with MCI compared with no treatment, but there were no effects when compared with an active control group.9 More recent reviews have included RCT and non-RCT studies and systematic reviews identified in the search and contacted experts. We included RCTs evaluating any treatment for MCI that or a separately analysed subgroup had MCI.

Conclusions
There was no replicated evidence that any intervention was effective. Cholinesterase inhibitors and rofecoxib are ineffective in preventing dementia. Further good-quality RCTs are needed and preliminary evidence suggests these should include trials of psychological group interventions and piribedil.

Declarations of interest
C.L. has received grant support (research or continuing medical education) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil, Bristol-Myers Squibb, Novartis, National Football League (NFL), Elan, Functional Neuromodulation; and has been a consultant/advisor to AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, Bristol-Myers Squibb; and received honorarium or travel support from Pfizer, Forest, GlaxoSmithKline, Health Monitor.
Data extraction

One author (C.C.) extracted study characteristics (online Tables DS1 and DS2). We contacted two authors to request unreported data; and obtained this for one13,15 but not the second study.

To assess risk of bias, two authors (C.C. and R.L.) independently evaluated study validity using questions adapted from the Critical Appraisal Skills Programme (CASP; www.hello.nhs.uk/documents/CAT6-Randomised_Controlled_Trials.pdf).

(a) Were participants appropriately allocated to intervention and control groups? (Was randomisation independent?)
(b) Were patients and clinicians, as far as possible, ‘masked’ to treatment allocation?
(c) Were all patients who entered the trial accounted for and an intention-to-treat analysis used?
(d) Were all participants followed up and data collected in the same way?
(e) Was a power calculation carried out, based on one of our outcomes of interest?

Disagreements were resolved by consensus between authors.

Analysis

We compared control and intervention groups post-intervention. We prioritised results from placebo-controlled studies that identified one or two primary outcomes, as these were less likely to have reported significant chance findings. For primary outcome results we displayed standardised outcomes in Forest plots (standardised mean difference (SMD), standardised mean change (SMC)), hazard ratios (HR) or odds ratio (OR)) for primary outcomes using statsdirect statistical software version 2.7.9 on Windows;16 for some studies where these results were unavailable we calculated SMD or SMC from mean (or mean change), appropriate standard deviations and n for intervention and control groups post-intervention. Our calculations sometimes indicated a significant between-group difference where the authors’ multivariate calculations did not, or vice versa, and we have indicated in the text where this occurred. For all other results we tabulated statistical comparisons between groups, and for the few studies where groups were not directly compared calculated SMD as above. We planned to meta-analyse results where three or more studies with comparable interventions reported comparable outcomes.

Results

Figure 1 shows a PRISMA diagram describing the results of our search strategy. We included 41 unique studies and listed excluded studies in online supplement DS1. Five Chinese studies were translated by R.L.; the remainder were published in English.

Validity

Table DS1 describes the 20 (49%) studies that identified one or two primary outcomes: 16 were placebo-controlled and 13 used intention-to-treat analyses. Other studies are displayed in Table DS2. We rated the overall validity of studies (see methods). In total, 11 of 20 studies that identified primary outcomes and 5 of 23 studies that did not had validity scores of 4 or 5, the highest levels of evidence.

Description of studies

Included studies recruited people with MCI via clinics or clinician referrals,17–28 advertisements,24,29–34 screening older populations,21,35–38 care homes,23,39–41 the local Alzheimer’s society,34 pre-existing research registers,31,42 a rehabilitation centre33 or a welfare institution.25 Several did not report the source of participants.11,13,44–52 Tables DS1 and DS2 describe funding sources, inclusion criteria, sample sizes, comparators and the duration of studies. Figures 2–5 report results on all primary outcomes for which standardised outcomes could be calculated; this was not possible for four studies 14,21,51,53 because data were not available or did not approximate the normal distribution, so these results are described in the text. In Table DS2, we report statistically significant between-group differences from studies without primary outcomes. Non-significant findings for all studies are in Tables DS3 and DS4. The only intervention evaluated in more than two studies was donepezil; three donepezil trials included the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) at 6 months, but as data were not available from one, we could not meta-analyse these findings.

Findings on primary outcomes in placebo-controlled studies

Cognition improved in small studies of group memory training, cognitive stimulation and reminiscence over 6 months; and piribedil, a dopamine receptor agonist over 3 months.23 In a large, adequately powered study, donepezil improved cognition compared with placebo with 48 weeks’ treatment.15 Nicotine patches improved attention in a small study of non-smokers over 6 months which was adequately powered to detect a difference on this outcome.21 Huannao Yicong, a Chinese herbal preparation containing ginseng, demonstrated efficacy on a measure of cognition and social functioning over 8 weeks in a small per protocol, responder analysis, but not when mean scores were compared between groups.28

The only finding replicated on primary outcome measures involved galantamine51 (in two studies) and other cholinesterase inhibitors (in two studies31,42) that did not prevent conversion to dementia. In adequately powered trials, conversion to dementia was also not reduced by vitamin E45 or Gingko biloba.25 Rofecoxib, in an adequately powered study increased dementia
Treatments for mild cognitive impairment

Mixed-group intervention (ADAS-Cog)\textsuperscript{19} 1.00 (0.60 to 1.90)
Mixed-group intervention (MMSE)\textsuperscript{19} 1.50 (0.70 to 2.20)
Fish oils (ADAS-Cog)\textsuperscript{29} −0.06 (−0.80 to 0.70)
Fish oils (CIBIC)\textsuperscript{29} 0.60 (−0.20 to 1.20)
Donepezil (ADAS-Cog)\textsuperscript{15} 0.10 (0.03 to 0.20)
Donepezil (CDR-SB)\textsuperscript{15} 0.10 (−0.02 to 0.10)
Trifusul (ADAS-Cog)\textsuperscript{44} 0.10 (−0.08 to 0.30)
Walking group, men (AVLT)\textsuperscript{38,54} 0.10 (−0.46 to 0.42)
Walking group, women (AVLT)\textsuperscript{38,54} 0.10 (−0.64 to 0.43)
B vitamins, men (AVLT)\textsuperscript{38,54} 0.26 (−0.70 to 0.18)
B vitamins, women (AVLT)\textsuperscript{38,54} 0.29 (−0.23 to 0.81)
Family intervention (prospective memory, PI)\textsuperscript{20} 0.40 (−0.20 to 1.00)

**Fig. 2** Forest plots showing between-group comparisons for studies with outcomes expressed as standardised mean difference (with 95% confidence intervals).

ADAS-Cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; MMSE, Mini-Mental State Examination; CIBIC, Clinician’s Interview-Based Impression of Change; CDR-SB, Clinical Dementia Rating scale – Sum of Boxes; AVLT, Rey Auditory Verbal Learning Test; PI, post-intervention.

Cognitive training (RBANS)\textsuperscript{18} 0.33 (−0.26 to 0.92)
Rivastigmine (cognition)\textsuperscript{31} −0.10 (−0.63 to 0.44)
Donepezil (NYPT)\textsuperscript{45} 0.10 (−0.10 to 0.40)
Gingko biloba (memory)\textsuperscript{25} 0.42 (0.05 to 0.80)
Gingko biloba (picture recognition)\textsuperscript{25} 0.46 (0.09 to 0.84)

**Fig. 3** Forest plots showing between-group comparisons for studies with outcomes expressed as standardised mean change from baseline (with 95% confidence intervals).

RBANS, Repeatable Battery for Assessment of Cognitive Status; NYPT, New York Paragraph Test.

**Fig. 4** Forest plots showing between-group comparisons for studies reporting hazard ratios (95% CI) for incident dementia or Alzheimer’s disease (log scale).
Non-pharmacological interventions

Computer-assisted cognitive training (three studies)

All three studies were probably underpowered although results were not promising there was insufficient evidence to draw conclusions about its efficacy. Only Barnes et al. \(^{48}\) specified primary outcomes (validity score: 4). They evaluated a programme that involved distinguishing between similar sounding words and matching sentences with pictures, for 100 min daily, 5 days a week. The control group listened to audio books, read an online newspaper and played a computer game. There was no significant difference between groups on the primary outcome, the Repeatable Battery for Assessment of Cognitive Status (RBANS) after 6 weeks (Fig. 3). The only significant difference, favouring the intervention, was on the delayed memory RBANS subscale (SMD = 0.53, 95% CI 0.05–1.10).

Two studies tested computer-assisted training, but did not specify primary outcomes. Finn & McDonald\(^ {55}\) evaluated a 2-month programme in a higher-quality study (validity score: 4), and Rozzini et al.\(^ {47}\) a 9-month programme (validity score: 3). In both studies, most results were not significant; only results for the visual attention CANTAB (Cambridge Automated Neuropsychiatric Test Assessment Battery) subscale\(^ {25}\) and short story recall\(^ {47}\) favoured the interventions (Table DS2).

**Summary.** Global cognition did not improve with cognitive training in two trials,\(^ {16,4}\) in one of which it was a primary outcome, and there were no consistently significant findings on other secondary outcomes. Studies were all underpowered.

Longer-term group psychological interventions (two studies)

Two lower-quality studies tested 6-month group interventions. Results were conflicting. Buschert et al.\(^ {49}\) (validity score: 3 and primary outcomes specified) tested a manualised memory training and cognitive stimulation programme, consisting of 20 2 h weekly group sessions comparing 10 people in the intervention group with 12 in the control group. The memory training used mnemonics, calendars, notes and prompts; face–name association and errorless learning. In errorless learning, information was repeated frequently to avoid recall mistakes, with repetitions becoming further apart with successful recalls (spaced retrieval). The programme also included reminiscence, psychomotor and recreational tasks (for example playing with balloons), multisensory stimulation and social interaction. Participants did homework, which carers were encouraged to support. The control group met monthly and did paper-and-pencil exercises. Only participants who attended at least half of sessions were included in analyses. Global cognition, the primary outcome, improved in the intervention group in our univariate (Table DS1) and the authors’ analyses that controlled for baseline score, age and educational status on both primary outcome measures. Montgomery–Åsberg Depression Rating Scale scores were also lower in the intervention compared with the control group adjusting for these factors (mean 0.7 (s.d. = 1.3) for treatment group and 3.8 (s.d. = 6.1) for controls, F(1,18) = 8.8, P<0.01).

Troyer et al.\(^ {24}\) in a small study (validity score: 1), evaluated 10 2 h sessions, including psychoeducation, recreation, memory training and strategies, relaxation and directing to community resources. The authors found no significant differences between groups post-intervention on several measures of recall (Table DS4).

**Summary.**

(a) Twenty sessions of memory training, reminiscence, cognitive stimulation, psychomotor recreation and social interaction improved global cognition on a primary outcome in a single, very small, 6-month placebo-controlled trial that did not carry out an intention-to-treat analysis.\(^ {19}\)

(b) Ten sessions of memory training, psychoeducation and relaxation did not improve recall on secondary outcomes in one small 6-month trial.\(^ {24}\)

Short-term (6-week) psychological group interventions (two studies)

Both studies were lower quality (validity score: 2) and were underpowered so although neither improved memory there was insufficient evidence to reject this intervention type. Unverzagt et al.\(^ {14}\) specified primary outcomes and compared three interventions, all of ten sessions teaching specific cognitive strategies, with a no-treatment control. The interventions were: memory training strategies; reasoning training; and processing speed.
training. Booster training was provided to 60% of participants, approximately 11 months later. Memory training participants did not improve post-intervention, or 1 or 2 years later on the composite memory measure \( v \), those receiving no treatment (SMD = \(-0.01, 95\%\) CI \(-0.18\) to \(-0.10, P > 0.05\)). Participants receiving the processing speed intervention improved on processing speed (SMD = \(-1.4, 95\%\) CI \(-1.1\) to \(-0.8, P < 0.001\)) and the reasoning group participants improved on reasoning post-intervention (SMD = 0.57, \( P < 0.001\)) and 2 years (SMD = 0.28, \( P < 0.05\)), but not 1 year later (SMD = 0.21, \( P > 0.05\)), compared with those receiving no treatment.

Rapp et al.\(^4\) did not specify primary outcomes. They evaluated six weekly 2 h sessions, of psychoeducation, relaxation, memory strategies (cuing, categorisation, chunking, method of loci) and homework. Participants received a manual, which was also sent to the control group who otherwise had no treatment. There were no significant differences between groups on several memory measures, post-intervention or 6 months later.

**Summary.**

(a) Memory did not improve over 6 weeks in two short-term, underpowered group intervention trials teaching memory strategies, which were not placebo-controlled.\(^14\),\(^46\)

(b) Specific interventions to improve reasoning and processing speed respectively significantly improved these primary outcomes, in an underpowered single, non-placebo-controlled trial.\(^4\)

**Family psychological interventions (one study)**

This lower-quality study indicated that a family psychological intervention might improve prospective memory. Kinsella et al.\(^20\) (validity score: 2) compared a course of five weekly 1.5 h family intervention sessions to a waiting list control. Sessions involved problem-solving everyday memory difficulties and practising possible strategies. Written session material was provided. Results on the primary outcome, an unvalidated (to our knowledge) prospective memory test favoured the intervention 2 weeks and 4 months post-intervention, controlling for baseline scores and age; the SMD for this comparison was not significant in our univariate analysis (Fig. 2).

**Summary.** Prospective memory improved up to 4 months later in this underpowered trial that was not placebo-controlled, on a non-validated measure, but only when baseline memory scores were taken into account.\(^29\)

**Individual psychological interventions (one study)**

This lower-quality study (validity score: 3) found that an individual psychological intervention did not improve memory. Jean et al.\(^33\) evaluated six individual 45 min sessions over 3 weeks, focusing on errorless learning of picture–name associations with spaced retrieval (see earlier). In the control condition, the pictures were presented without spaced retrieval. Participants were given written information about memory. The unvalidated primary outcomes evaluated the number of unknown faces (episodic memory) and famous names (semantic memory) matched correctly. There was no significant treatment effect on these measures in mixed-linear models (\(F(2,35) = 49.390, F(2,35) = 11569\)), or on Mini-Mental State Examination (MMSE).

**Summary.** Six individual sessions of errorless learning and spaced retrieval did not improve prospective memory in one placebo-controlled, underpowered study where this was a primary outcome.\(^53\)

**Exercise**

Exercise has been associated with favourable effects on neuronal survivability and function, neuroinflammation, vascularisation, neuroendocrine response to stress and brain amyloid burden. It also improves cardiovascular health, which is associated with cognitive health.\(^47\)

**Group exercise programmes (two studies).** Results from two studies comparing year-long, twice-weekly, group-based exercise programmes to active control conditions were mixed. In a very high-quality study (validity score: 5), van Uffelen et al.\(^38,\)^\(^54\) compared a moderate-intensity walking programme to low-intensity relaxation, balance and flexibility exercises, and found no significant effect in any cognitive domain, including the primary outcome of immediate word recall (Fig. 2) or in quality of life. In a lower-quality study (validity score: 3; no primary outcomes specified), Suzuki et al.\(^42\) compared groups involving circuit training and some outdoor walking with a control group who attended three health promotion classes. The intervention group improved in terms of MMSE score, immediate memory and verbal fluency (Table DS2).

**Individual exercise programmes (three studies).** None of these lower-quality studies specified primary outcomes. Busse et al.\(^6\) (validity score: 3) evaluated 9 months of resistance exercises, for 1 h twice a week. Scores on a test of everyday memory (Rivermead Behaviour Memory Test) improved in the intervention group relative to the no-treatment controls, but CAMCog (Cambridge Cognition Examination) scores and digit span did not.

The remaining two studies had validity scores of 2. Baker et al.\(^17\) compared cognition in adults exercising less than 90 min weekly participating in a 6-month high-intensity aerobic exercise intervention or a stretching and balance exercise control. Each intervention was for 1 h 4 days a week. The first eight sessions, and thereafter one session a week, were supervised. Adherence was monitored. Significant between-group effects, favouring the intervention, were reported on the Digit Symbol Substitution Test (DSST) (attention and processing speed), trail making test B and verbal fluency (Table DS2). For verbal fluency, effects were more apparent for category than letter fluency (letter, \(P = 0.20\), category, \(P = 0.03\)). Scherder et al.\(^41\) compared: assisted walking for 30 min, 3 days a week for 6 weeks; hand and face exercises for the same duration; and a control group, half of whom received additional social visits. The only significant between-group differences, all in favour of the interventions, were on the category fluency and trail making tests (Table DS2).

**Summary.**

(a) A very high-quality study found that memory, the primary outcome, did not improve with a year-long aerobic exercise group compared with a relaxation, balance and flexibility exercise active control group.\(^38,\)^\(^54\) A lower-quality study found that participants in a similar intervention improved on fluency, memory and global cognition relative to a health promotion control.\(^52\)

(b) The studies of individual exercise studies were low quality and their results were inconsistent.\(^17,\)^\(^20,\)^\(^41\) Category fluency and trail-making test scores improved with individual aerobic exercise on secondary outcomes in two studies, of 6 weeks and 6 months duration, but no other cognitive outcomes improved in more than one study.
Pharmacological interventions

Cholinesterase inhibitors (nine studies)

Three large studies compared donepezil 10 mg daily to placebo, and results were inconsistent. The highest-quality one (validity score: 5) by Doody et al.15 was a 48-week study that included two primary outcome measures: ADAS-Cog, on which results favoured donepezil, and the Clinical Dementia Rating (CDR) on which there was no significant between-group difference (Fig. 2). On secondary outcomes, only patient global assessment differed significantly between groups, in favour of donepezil. The two other large studies were higher-quality studies (validity score: 4). Salloway et al.48 carried out a 24-week, adequately powered study and there were no significant differences between donepezil and placebo on the primary outcomes, the New York University Paragraph Delayed Recall test or the Clinician Global Impression of Change (CGIC), or on any secondary outcomes except for the ADAS-Cog. Petersen et al.45 found no significant difference between groups on conversion to Alzheimer’s disease, the primary outcome (Fig. 3) or any other measures over 3 years. One small, lower-quality study (validity score: 1) that did not identify primary outcomes found that donepezil and antidepressant treatment improved immediate memory but not other cognitive outcomes, compared with antidepressants alone.27

Galantamine was investigated in three trials, and results on primary outcomes in the highest-quality trials were not significant. Winblad et al.51 evaluated galantamine, titrated to 12 mg twice daily in two large, high-quality, 24-month, placebo-controlled RCTs (validity scores 5). Neither reported a significant effect on the primary outcome, incident dementia (developing dementia in intervention 22.9% v. control group 22.6%, \( P = 0.15 \), 25.4% v. 31.2%, \( P = 0.62 \)). On secondary measures, statistical comparisons favoured galantamine in one of the two studies for global functioning (measured on the CDR) and attention (DSST). In a small, lower-quality trial, Koontz & Baskys22 only reported significant between-group differences on two subscales of the CANTAB, both measuring executive functioning (Table DS2).

One high-quality study (validity score: 5), by Feldman et al.51 compared 3–12 mg daily of rivastigmine and placebo. There were no significant differences between participants on any measures over 2 years, including the primary outcome, progression to Alzheimer’s disease (Fig. 3).

Finally, Rozzini et al.47 compared people receiving any cholinesterase inhibitor to those taking placebo after 1 year in a lower-quality study (validity score: 2). There were no significant between-group differences on any measures (Table DS4).

Summary.

(a) Incident Alzheimer’s disease was not reduced in four, higher-quality trials where this was the primary outcome – two evaluated galantamine, one donepezil, and one rivastigmine.31,43,51

(b) Donepezil improved global cognition in one high-quality trial where it was a primary outcome measure,15 and a second where it was a secondary outcome,46 but global cognition did not improve in the five other large, high-quality trials of cholinesterase inhibitors.7,15,47,51

(c) Donepezil did not improve global functioning in one trial where this was a primary outcome.15 Galantamine improved global functioning in one trial on a secondary outcome measure.51

(d) Galantamine improved executive functioning and attention on secondary outcome measures in a single trial.51

(e) Donepezil as an adjunct to antidepressants improved immediate memory, also on a secondary outcome.27

Piribedil (one study)

Piribedil is a dopamine receptor agonist. Animal models have suggested acetylcholine release in hippocampi and the frontal cortex as a putative mechanism of action. Nagaraja & Jayashree23 evaluated this over 3 months in a higher-quality trial (validity score: 4) with 30 in each group, all with a MMSE of 21–25; the primary outcome, response on the MMSE (predefined as a score of 26+), favoured piribedil (Fig. 5). Mean MMSE change from baseline also favoured the intervention group (\( t = 283, P < 0.01 \)). It was well tolerated.

Summary. Piribedil improved cognition over 3 months on a primary outcome in one small placebo-controlled study.25

Nicotine (one study)

Brain nicotinic receptors are important for cognitive function.21 Newhouse et al.41 compared transdermal nicotine (titrated to a 15 mg patch/day) to placebo in a very high-quality study (validity score: 5, with primary outcomes specified). Attention, measured on the Connors Cognitive Performance Test improved (\( F = 4.89, P = 0.031, \) effect size 0.78) but global functioning on the CGIC did not, on mixed-models repeated-measures analyses of variance. On secondary outcome measures, the treatment group showed less forgetting in between immediate and delayed recall than placebo (\( F = 4.42, P = 0.04 \)), better delayed word recall (\( F = 5.92, P = 0.018 \)) and less anxiety on the older Adult Self Report worries and anxiety subscales (\( F = 3.48, P = 0.04; F = 3.14, P = 0.05 \)).

Summary. Nicotine patches improved attention, but not global functioning, over 6 months on primary outcomes in one, high-quality study.21 Delayed recall and self-reported anxiety improved on secondary outcomes.

Huannao Yicong (one study)

Li et al.28 evaluated this Chinese medicinal compound, which includes ginseng, in a study that identified primary outcomes but was low quality (validity score: 0). Increases or changes in hippocampal mitochondria have been proposed as mechanisms of action. Over 2 months, comparisons favoured the intervention on the primary outcome, response (improvement of 6+ points) on the Cognitive Effect Index (CEI), which comprised the MMSE, Cognitive Capacity Screening Examination (CCSE) and a social functioning scale (Short-Form (SF)-36, Chinese version). We found that the mean difference in CEI scores between groups post-treatment was not significant (Table DS1). The analyses excluded people who did not take their medication.

Summary. Results in one low-quality trial were equivocal: more participants taking Huannao Yicong than placebo responded on a cognition and social functioning measure, but the mean difference between groups on this measure was not significant.28

Gingko biloba (two studies)

Results from these studies were inconsistent, but the highest-quality trials suggested it is ineffective. Proposed mechanisms of action of Gingko biloba include increasing brain blood supply, reducing blood viscosity, modifying neurotransmitter systems, and reducing oxygen free radical density.56 A very high-quality study (validity score: 5, published in two papers: deKosky et al.55
and Snitz et al. found that 240 mg daily, taken for a median of 6.1 years, did not reduce incident dementia or Alzheimer’s disease. In a lower-quality (validity score: 3), 6-month study that was not placebo controlled, Zhao et al. reported that participants prescribed 56.7 mg daily Gingko biloba performed better than those receiving no treatment on nonsense picture recognition and logical memory tests (Fig. 3).

Summary. On primary outcomes, 240 mg daily Gingko biloba did not reduce incident dementia in a very high-quality trial over 6 years; whereas 56.7 mg daily improved cognition in a second trial compared with usual treatment.

NSAIDs (two studies)
Non-steroidal anti-inflammatory drugs reduce brain neuroinflammatory responses, so could improve cognition. Thal et al. in a very high-quality large study (validity score: 5), found significantly more incident cases of Alzheimer’s disease over 4 years in participants randomised to 25 mg daily of rofecoxib (a COX-2 inhibitor) than those taking placebo (Fig. 4). There was no significant difference between groups on secondary outcomes. In 2003, rofecoxib was withdrawn due to cerebrovascular and cardiovascular side-effects.

Gomez-Isla et al. evaluated 900 mg a day of triflusal, a COX-1 and COX-2 inhibitor in a lower-quality study (validity score: 3), which was terminated early. It found no significant difference between groups on the primary cognitive outcome, ADAS-Cog (Fig. 2). The only significant finding on secondary outcomes was a lower rate of conversion to Alzheimer’s disease in the intervention group (HR = 210, 95% CI 1.10–4.01, P = 0.024).

Summary. (a) Rofecoxib increased incident cases of Alzheimer’s disease in one very high-quality study on a primary outcome.

(b) One trial of triflusal reported no significant effect on cognition on a primary outcome measure, although it was associated with a reduced risk of conversion to Alzheimer’s disease on a secondary outcome.

B vitamins (two studies)
Higher homocysteine plasma concentrations are associated with cognitive impairment; levels are decreased by B vitamins. Two placebo-controlled trials investigated the effectiveness of B vitamins (folic acid, B₁₂ and B₆). In a very high-quality study (validity score: 5 and primary outcome specified), van Uffelen et al. found no significant difference on the primary outcome of immediate memory over 6 months. On secondary outcomes, the group taking vitamins performed better than the placebo group on the DSST (attention and processing speed; longitudinal regression, coefficient not given, P = 0.02). De Jager et al. found in a lower-quality (validity score: 3), 2-year study that executive functioning improved relative to placebo (Table DS2).

Summary. Immediate memory did not improve in a high-quality study in which this was primary outcome. Out of numerous secondary measures, attention improved in one trial and executive functioning in another, so results were inconsistent.

Vitamin E (two studies)
One large, higher-quality trial (validity score: 4) reported by Petersen et al. found no significant treatment effect of vitamin E (2000 IU) on the primary outcome measure, progression to Alzheimer’s disease or on a range of secondary outcomes over 3 years. Zhou et al. reported in a lower-quality study (validity score: 1) that participants receiving vitamin E 500 mg daily improved vs. placebo on picture recognition (Table DS2).

Summary. (a) Vitamin E did not reduce incident dementia in one high-quality study on a primary outcome.

(b) In a lower-quality study 500 mg daily was associated with improvement in picture recognition, a secondary outcome.

Omega-3 polyunsaturated fatty acids (two studies)
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are dietary polyunsaturated fatty acids (PUFA), which have structural and functional roles in the brain. Both these studies had validity scores of 3. Chiu et al. found that, as primary outcomes, ADAS-Cog improved over 6 months in people taking 1080 mg EPA and 720 mg DHA vs. placebo after adjusting for age, gender and education, but no differences were reported on the Clinician’s Interview-Based Impression of Change (CIBIC-plus, global functioning). When we calculated SMD for ADAS-Cog at follow-up between groups, there were no significant differences (Table DS1).

Sinn et al. in a small study compared groups receiving EPA-rich fish oil (1670 mg EPA and 160 mg DHA) and DHA-rich fish oil (1550 mg DHA and 400 mg EPA) with a placebo group. Using a linear-mixed model analysis, letter fluency scores significantly improved over 6 months in the DHA group vs. placebo, and depressive symptoms, measured using the Geriatric Depression Score, were reduced in both groups (Table DS2).

Summary. (a) Cognition improved on a primary outcome in one study, but only after adjusting for age, gender and education.

(b) Verbal fluency improved with DHA-rich fish oil and depressive symptoms were reduced by DHA- and EPA-rich oil after 6 months in a single small study on secondary outcome measures.

Interventions evaluated in single trials without primary outcomes
Ten different interventions have been evaluated in single trials, not specifying one or two primary outcomes (Table DS2). Three were higher-quality trials (validity scores 4+). The first found that transcutaneous electrical nerve stimulation (TENS) treatment reduced activities of daily living impairment and depression over 6 weeks in the only trial we reviewed that did not measure cognition. The second trial found that in 3-month trials, memantine improved information processing speed but not cognition. The third found that a nutritional supplement composed of: DHA 720 mg, EPA 286 mg, vitamin E 16 mg, soy phospholipids 160 mg, tryptophan 95 mg and melatonin 5 mg improved cognition.

Fluoxetine. Shenin oral liquid, Ginseng, Wuzi Yanzong, grape juice. Green tea and lithium were ineffective in single, lower-quality trials.

Discussion

Main findings
Our most striking finding is the lack of good-quality evidence except in the pharmacological trials. These enable us to more
confidently reject cholinesterase inhibitors as useful in preventing conversion of MCI to dementia, and to confirm NICE guidance that cholinesterase inhibitors should not be prescribed clinically for MCI. The only non-pharmacological intervention for which we found preliminary evidence, in a single, placebo-controlled trial on co-primary outcomes, was a heterogeneous group programme of memory training, reminiscence and cognitive stimulation, recreation and social interaction, which improved cognition over 6 months. There was equivocal evidence that a group intervention for families might improve prospective memory from a trial that was not placebo controlled. We also found replicated evidence on secondary outcomes that category fluency improved with individual aerobic exercise programmes, of 6 weeks and 6 months duration, and delayed recall improved in two studies evaluating computerised cognitive training programmes. These latter studies had multiple secondary outcomes, thus increasing the possibility of a chance finding and the clinical benefit of isolated improvements in these domains is unclear. Most studies were underpowered and lack of evidence of efficacy is not evidence of lack of efficacy.

In pharmacological studies, donepezil improved cognition over a year in two trials, one on a primary outcome, but in general the evidence from seven studies of cholinesterase inhibitors was not promising. The strongest evidence we found was that cholinesterase inhibitors did not reduce the incidence of dementia. Given the safety concerns around the use of cholinesterase inhibitors in MCI, we think that trials of alternative therapeutic agents are now needed.

Piribedil, a dopamine agonist was effective on a cognitive primary outcome in one study. However, the criteria for MCI were not strict and the authors acknowledge that some of the participants may have had dementia. Nicotine patches improved attention on a primary outcome over 6 months, and also verbal recall on a secondary outcome; and we found equivocal evidence that Huannao Yicong, a Chinese herbal preparation, may improve cognition and social functioning.

It is disappointing that we did not find stronger evidence of efficacy, but nonetheless some of the interventions included warrant further investigation. It is unclear why there have been no further trials of piribedil in MCI since the positive trial reported in 2001; a trial of piribedil in people with Parkinson’s disease has not yet reported (ClinicalTrials.gov identifier: NCT01007864). The effectiveness of Huannao Yicong in one trial, albeit of low validity, could indicate that further exploration of Chinese medicine treatments of MCI may be fruitful. There was limited evidence that exercise therapies improved executive functioning. Resistance training, walking and aerobic exercises may well differ in their effects, and given the positive impact of exercise on general health this would also be an interesting area for future study.

**Limitations**

This is one of the first comprehensive reviews of all treatments evaluated for MCI. Methodological challenges for MCI trials include deciding inclusion criteria. Nearly two-thirds of studies used Petersen criteria. Some of the studies only included participants with amnestic MCI, whereas others included other subtypes so even within those using Petersen criteria, the target groups were heterogeneous. Some people with MCI have prodromal Alzheimer’s disease or will progress to vascular or other subtypes of dementia. Only two-thirds of people with MCI progress to dementia in their lifetime, limiting the power of secondary prevention studies that recruit MCI populations. The heterogeneity and instability of the MCI diagnosis militate against finding positive results in MCI trials. It is interesting that although in the trial reported by Petersen et al., vitamin E did not prevent Alzheimer’s disease in people with amnestic MCI overall, it was effective at doing so among carriers of one or more apolipoprotein E4 alleles, perhaps because this is a more homogeneous group, more likely to have prodromal Alzheimer’s disease. Availability of biomarkers may enable future trials to recruit participants according to disease process rather than clinical deficits. For example, trials of pharmacological agents targeting people with early Alzheimer’s disease may recruit people with amnestic MCI and probable Alzheimer’s disease. Biomarkers may also allow participants to be recruited earlier in the disease process, at the stage of subjective memory impairment, which usually precedes MCI. By the time MCI develops the pathological process may be too advanced for treatments to be preventive, perhaps because the brain is by this point very vulnerable to other comorbidities that lead to a dementia, even though progression of the original pathology is halted.

A second challenge is deciding on a primary outcome. ‘Conversion’ trials are difficult to power adequately as only 10% of people with MCI convert every year to dementia, and this rate seems to be lower in RCTs. Incident dementia is often the primary outcome as dementia prevention is a clear goal, but Schneider has suggested it is a problematic end-point because many participants would be on the cusp of dementia and dementia onset is influenced by numerous biological and environmental factors. We prioritised placebo-controlled trials, because this evidence is most directly applicable to current practice. There are no evidence-based interventions for MCI and most people with it receive no active treatment. We included a broad range of clinical outcomes, but excluded studies evaluating subjective experiences of memory or biological markers. We included papers in all languages, but only searched English language databases. We planned to meta-analyse findings from three or more studies, but in practice only donepezil was evaluated in more than two studies, and this could not be meta-analysed as the required data were unavailable from one study.

**Implications**

There is no evidence, replicated on primary outcomes, that any intervention is effective for MCI for the outcomes studied. Results for cholinesterase inhibitors in MCI, the most widely studied intervention, are unpromising. More high-quality RCTs are urgently needed. This review would support further trials of a heterogeneous group psychological intervention and a dopamine agonist as interventions targeting cognition.

---

**References**

Daswanth was born in India in 1560. He was the son of a palanquin bearer who transported people belonging to social classes many levels higher than his own. Despite this humble background, Daswanth’s gifts were discovered by the Mughal emperor Akbar, a connoisseur of art, who would often canvass his domain looking for potential talent to beautify his courthouses and other public buildings. Emperor Akbar had noticed Daswanth’s talent and sent him to the local painting master for a period of intensive training.

Rumours circulated about a disquieting side to the young painter. His behaviour was thought to be impulsive, even irrational at times. Images arise of a wildly eccentric artist depicting his foreboding visions with ominous intensity. Among the most vivid of Daswanth’s surviving works is ‘A Night Assault on the Pandava Camp’. This morbid masterpiece depicts a mythical spirit feasting on the blood of battle victims. In the bloody scene, a sultry female demon delights in her necklace of decapitated heads and garments consisting of the skins of slaughtered animals. Adding to the chaos is a certain stylistic distortion, in which lines overlap and lead to spatial ambivalence.

The irrational and alarming qualities of Daswanth’s work began to surface more often in his behaviour. Whatever could be done for him in this era, one can only conjecture. What is certain is that the era in which he lived far pre-dated the advent of modern psychiatry, and there was therefore nothing to prevent his fall into a maelstrom of self-destruction.

Daswanth’s demise would only serve to reinforce his ‘madman’ image, as at the mere age of 24 he fatally stabbed himself. At present, few paintings can be confidently attributed to Daswanth. Of these, most are found in a richly illustrated Indian manuscript produced during the late 16th century.

Daswanth
Raymond Cavanaugh Jr

Daswanth was born in India in 1560. He was the son of a palanquin bearer who transported people belonging to social classes many levels higher than his own. Despite this humble background, Daswanth’s gifts were discovered by the Mughal emperor Akbar, a connoisseur of art, who would often canvass his domain looking for potential talent to beautify his courthouses and other public buildings. Emperor Akbar had noticed Daswanth’s talent and sent him to the local painting master for a period of intensive training.

Rumours circulated about a disquieting side to the young painter. His behaviour was thought to be impulsive, even irrational at times. Images arise of a wildly eccentric artist depicting his foreboding visions with ominous intensity. Among the most vivid of Daswanth’s surviving works is ‘A Night Assault on the Pandava Camp’. This morbid masterpiece depicts a mythical spirit feasting on the blood of battle victims. In the bloody scene, a sultry female demon delights in her necklace of decapitated heads and garments consisting of the skins of slaughtered animals. Adding to the chaos is a certain stylistic distortion, in which lines overlap and lead to spatial ambivalence.

The irrational and alarming qualities of Daswanth’s work began to surface more often in his behaviour. Whatever could be done for him in this era, one can only conjecture. What is certain is that the era in which he lived far pre-dated the advent of modern psychiatry, and there was therefore nothing to prevent his fall into a maelstrom of self-destruction.

Daswanth’s demise would only serve to reinforce his ‘madman’ image, as at the mere age of 24 he fatally stabbed himself. At present, few paintings can be confidently attributed to Daswanth. Of these, most are found in a richly illustrated Indian manuscript produced during the late 16th century.
### Table DS1 Characteristics and validity of studies specifying one or two primary efficacy outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Support sources</th>
<th>Inclusion criteria</th>
<th>Treatment group</th>
<th>Control group</th>
<th>Duration</th>
<th>Primary outcome</th>
<th>Validity*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barnes et al</td>
<td>Posit Science, Gov (USA)</td>
<td>Cognitive complaint n &gt;1 domain and no dementia</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>6 weeks</td>
<td>RBANS total score</td>
<td>y y y y n</td>
</tr>
<tr>
<td>Buschert et al</td>
<td>None declared</td>
<td>Age 50+, amnestic MCI</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>6 months</td>
<td>ADAS-Cog, MMSE</td>
<td>y y n y n</td>
</tr>
<tr>
<td>Chiu et al</td>
<td>Gov (Taiwan)</td>
<td>Amnestic MCI</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>6 months</td>
<td>ADAS-Cog, CIBIC</td>
<td>y y n y n</td>
</tr>
<tr>
<td>Dekosky et al</td>
<td>NCCAM Schwabe Pharmaceuticals</td>
<td>Age 75+, MO</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>6 years</td>
<td>Incident dementia</td>
<td>y y y y y</td>
</tr>
<tr>
<td>Doody et al</td>
<td>Eisai Pfizer</td>
<td>Age 45-90, MOc daily contact with informant</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>48 weeks</td>
<td>ADAS-Cog, CDR-SB</td>
<td>y y y y y</td>
</tr>
<tr>
<td>Feldman et al</td>
<td>Novartis</td>
<td>CDR: 0.5, &lt; 9 NYDPRT score, no dementia</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>2 years</td>
<td>Cognitive test battery Incident Alzheimer’s disease</td>
<td>y y y y y</td>
</tr>
<tr>
<td>Gomez-Isla et al</td>
<td>J. Uriach y Compana S.A.</td>
<td>SMC, MMSE &gt; 23, recall test &gt; 1.5 s.d. below expected and no dementia</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>13 months</td>
<td>ADAS-Cog</td>
<td>n y y y n</td>
</tr>
<tr>
<td>Jean et al</td>
<td>Gov (Canada) and Alzheimer society</td>
<td>Amnestic MCI</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>3 weeks</td>
<td>Episodic and semantic recall</td>
<td>n y n y y</td>
</tr>
<tr>
<td>Knisella et al</td>
<td>Alzheimer’s Australia, Hospital and University grant</td>
<td>Amnestic MCI</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>5 weeks</td>
<td>Prospective memory</td>
<td>n y y n n</td>
</tr>
<tr>
<td>Li et al</td>
<td>Not stated</td>
<td>MCI: aged 60-80 SMC, CDR 0-1 2-3 or CDR 0.5, no AML imp, MMSE 24-27</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>2 months</td>
<td>Cognitive effect Index</td>
<td>n n n n n</td>
</tr>
<tr>
<td>Nagaraja &amp; Jayashree</td>
<td>Gov (India) Serdia Pharmaceuticals</td>
<td>SMC, no dementia, agedPiribedil 50 mg od 60+ and MMSE 21-25</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>3 months</td>
<td>MMSE (responder)</td>
<td>n y y y y</td>
</tr>
<tr>
<td>Newhouse et al</td>
<td>Gov (USA), Pfizer</td>
<td>Amnestic MOd non-smoker</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>6 months</td>
<td>CPT MO2-CGIC</td>
<td>y y y y y</td>
</tr>
<tr>
<td>Petersen et al</td>
<td>Eisai, Pfizer Gov body (USA)</td>
<td>Age 55-90; amnestic MCI: CDR 0-5, MMSE 24-30; memory recall 15-20 s.d. below norm</td>
<td>Treatment n</td>
<td>Control group n</td>
<td>3 years</td>
<td>Incident Alzheimer’s disease</td>
<td>y y y y n</td>
</tr>
</tbody>
</table>
### Table DS1: Characteristics and validity of studies specifying one or two primary efficacy outcomes (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Support sources</th>
<th>Inclusion criteria</th>
<th>Treatment group</th>
<th>Control group</th>
<th>Duration</th>
<th>Primary outcome</th>
<th>Validity&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salloway et al&lt;sup&gt;28&lt;/sup&gt;</td>
<td>Eisai, Pfizer</td>
<td>Aged 55–90, SMC,</td>
<td>Donepezil titrated</td>
<td>Placebo</td>
<td>24 weeks</td>
<td>NYPDRT</td>
<td>n y y y y y y y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MMSE 24+, CDR 05</td>
<td>to 10 mg</td>
<td>133</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>137</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thai et al&lt;sup&gt;29&lt;/sup&gt;</td>
<td>Merck Research Laboratories</td>
<td>age 65+, SMC, MMSE&gt;23, CDR 05, BDRS&lt;3.5, AVLT&lt;38</td>
<td>Rofecoxib 25mg od</td>
<td>Placebo</td>
<td>&lt;4 years</td>
<td>Incident Alzheimer's disease</td>
<td>y y y y y y y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>129</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unverzagt et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Gov (USA)</td>
<td>AVLT 1.5 s.d. below predicted score, no dementia</td>
<td>10 x 1h group: memory training</td>
<td>No treatment</td>
<td>6 weeks, booster at 11 months</td>
<td>Memory, reasoning and speed composite measures&lt;sup&gt;g&lt;/sup&gt;</td>
<td>n y n y n n y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reasoning training</td>
<td>49</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speed training</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>van Uffelen et al&lt;sup&gt;35,36&lt;/sup&gt;</td>
<td>(Viatris; Gov, (The Netherlands))</td>
<td>MO&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Folic acid (5mg), vitamins B&lt;sub&gt;6&lt;/sub&gt; (04 mg) and B&lt;sub&gt;12&lt;/sub&gt; (50 mg) 2 x weekly, group walking</td>
<td>Placebo</td>
<td>1 year</td>
<td>AVLT 1–5 words</td>
<td>y y y y y y y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>78</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>74</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>74</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Winblad et al&lt;sup&gt;31,32&lt;/sup&gt;</td>
<td>Janssen-Cilag Johnson &amp; Johnson</td>
<td>CDR: 05, memory score &gt;05, age 50+</td>
<td>Galantamine 16-24mg od</td>
<td>Placebo</td>
<td>2 years</td>
<td>Incident dementia</td>
<td>y y y y y y y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>494</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>532</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhao et al&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Gov (China)</td>
<td>60–85, SMC, amnestic MCI&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Ginkgo biloba</td>
<td>Placebo</td>
<td>6 months</td>
<td>Memory test NPR</td>
<td>y n n n y y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Gov, national government supported funding source; RBANS, Repeatable Battery for Assessment of Cognitive Status; MO, mild cognitive impairment; ADAS-Cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; CBIC, Clinician’s Interview-Based Impression Change; NCCAM, National Center for Complementary and Alternative Medicine; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CDR-35, Clinical Dementia Rating scale – Sum of boxes; NYPDRT, New York University Paragraph Delayed Recall Test; SMC, subjective memory complaint; MMSE, Mini-Mental State Examination; GDS, Global Deterioration Scale; ADL imp, activities of daily living improvement; OPT, Connor Cognitive Performance Test (reaction time standard error change/interstimulus intervals); CGIC, Clinician Global Impression of Change; BDRS, Blessed Dementia Rating Score; AVLT, Rey Auditory Verbal Learning Test; NPR, nonsense picture recognition; od, once daily; bd, twice daily.

<sup>a</sup> See Method – numbers refer to questions asked about validity.
<sup>b</sup> Diagnosed according to Petersen criteria.
<sup>c</sup> Defined by International working group guidelines.
<sup>d</sup> Composite outcome measures tested; memory (mean Rey Auditory Verbal Learning Test, Hopkins Verbal Learning Test, and Rivermead Behavioral Memory Test z-scores), reasoning (mean Letter Series, Letter Sets, and Word Series tests), and processing speed (mean Useful Field of View task scores).
**Table DS2** Characteristics and validity of studies that do not specify one or two primary efficacy outcomes meeting inclusion criteria for this review, with number of outcomes and significant results

<table>
<thead>
<tr>
<th>Study (support source)</th>
<th>Inclusion criteria</th>
<th>Treatment group</th>
<th>Control group</th>
<th>Duration</th>
<th>Measures on which control and intervention groups differed significantly; post-intervention mean (s.d.) and statistical comparisons</th>
<th>Validity (answers to questions 1–5 in method)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Treatment</td>
<td>n</td>
<td>Control</td>
<td>Test</td>
<td>Intervention</td>
</tr>
<tr>
<td>Baker et al²⁷ (Gov, USA)</td>
<td>Amnestic MCI,a sedentary adults</td>
<td>6 months</td>
<td>14</td>
<td>17</td>
<td>DST</td>
<td>n/a</td>
</tr>
<tr>
<td>Busse et al²⁶ (not stated)</td>
<td>MCI,a sedentary adults</td>
<td>1 h, twice a week of resistance training</td>
<td>17</td>
<td>9 months</td>
<td>Rivermead Memory Behavioural Test</td>
<td>18.9</td>
</tr>
<tr>
<td>de Jager³⁰ (Gov, UK; charities)</td>
<td>Aged 70+; MCI,a 0.8 mg folate, 0.5 mg vitamin B₁₂ and 20mg vitamin B₆</td>
<td>110</td>
<td>Placebo</td>
<td>2 years</td>
<td>CDT correctly performed</td>
<td>Low H² 13.5(1.7) High H: 12.6(1.9)</td>
</tr>
<tr>
<td>Ferris et al³² (Forest Research Institute)</td>
<td>Aged 50–79; MMSE 27+; AAMI diagnosis</td>
<td>30</td>
<td>Placebo</td>
<td>3 months</td>
<td>Cogscreen Symbol Digit Accuracy</td>
<td>n/a</td>
</tr>
<tr>
<td>Finn &amp; McDonald³⁳ (Lumosity)</td>
<td>Aged 60+; MCI diagnosis, MMSE&lt;24</td>
<td>30 computerised cognitive training sessions, each with 4–5 exercises</td>
<td>Wait list</td>
<td>8 weeks</td>
<td>Visual sustained attention (CANTAB)</td>
<td>0.90 (0.09)</td>
</tr>
<tr>
<td>Forlenza et al³⁷ (Gov, Brazil; charities)</td>
<td>aged 60+, Mayo clinic amnestic MCI criteria</td>
<td>Lithium</td>
<td>21</td>
<td>Placebo</td>
<td>20</td>
<td>1 year</td>
</tr>
<tr>
<td>Fu et al³⁸ (Peking University; Gov, China)</td>
<td>MCI,a MMSE 24–27; no ChEI</td>
<td>Wuzi Yanzong granules 4.5 g sachets a drink, twice a day</td>
<td>18</td>
<td>Placebo</td>
<td>18</td>
<td>3 months</td>
</tr>
<tr>
<td>Koontz &amp; Baskys³⁹ (Janssen)</td>
<td>MCI,a MMSE &gt;25</td>
<td>Galantamine 12 mg bd</td>
<td>8</td>
<td>Placebo</td>
<td>11</td>
<td>16 weeks</td>
</tr>
<tr>
<td>Krilorian et al³² (Welch food)</td>
<td>SMC and CDR ‘mild’</td>
<td>Grape juice 444–621ml/d</td>
<td>5</td>
<td>Placebo</td>
<td>7</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Luipen et al³⁹ (Gov, The Netherlands)</td>
<td>MCI,a living in care home</td>
<td>TENS 30 min a day</td>
<td>17</td>
<td>Placebo</td>
<td>17</td>
<td>6 weeks</td>
</tr>
</tbody>
</table>

(continued)
### Table DS2: Characteristics and validity of studies that do not specify one or two primary efficacy outcomes meeting inclusion criteria for this review, with number of outcomes and significant results (continued)

<table>
<thead>
<tr>
<th>Study (support source)</th>
<th>Inclusion criteria</th>
<th>Treatment group</th>
<th>Control group</th>
<th>Duration</th>
<th>Measures on which control and intervention groups differed significantly; post-intervention mean (s.d.) and statistical comparisons</th>
<th>Validity (answers to questions 1–5 in method)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mowla et al</strong>&lt;sup&gt;43&lt;/sup&gt; (none stated)</td>
<td>MOCI&lt;sup&gt;a&lt;/sup&gt; and HRSD &lt;10</td>
<td>Fluoxetine titrated to 20 mg</td>
<td>Placebo</td>
<td>23</td>
<td>Treatment group</td>
<td>Control group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MMSE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Park et al</strong>&lt;sup&gt;33&lt;/sup&gt; (LG)</td>
<td>Aged 40–75, GLDS 2/3; MMSE 21–26; SuMC</td>
<td>Green tea extract and L-theanine</td>
<td>Placebo</td>
<td>45</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pelton et al</strong>&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Aged 50+, depression or memory clinic out-patients; SMC, NPT &gt;1 s.d. below normal; MMSE &gt;19; no ADL impairment</td>
<td>Antidepressant + donepezil</td>
<td>Placebo</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rapp et al</strong>&lt;sup&gt;46&lt;/sup&gt; (none stated)</td>
<td>MOCI&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6, weekly 2h groups, psychoeducation, memory skills and homework</td>
<td>Given manual</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rondanelli et al</strong>&lt;sup&gt;40&lt;/sup&gt; (none stated)</td>
<td>MOCI&lt;sup&gt;a&lt;/sup&gt;, MMSE 24+</td>
<td>Nutritional supplement (see text)</td>
<td>Placebo</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ronzini et al</strong>&lt;sup&gt;47&lt;/sup&gt; (not stated)</td>
<td>Aged 63–78, MOCI&lt;sup&gt;a&lt;/sup&gt; living independently, GDS &lt; 5</td>
<td>Neuropsychological training + ChEI</td>
<td>Given manual</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Scherder et al</strong>&lt;sup&gt;41&lt;/sup&gt; (Gov, The Netherlands)</td>
<td>MOCI&lt;sup&gt;a&lt;/sup&gt; and abbreviated MMSE score of 7+</td>
<td>ChEI</td>
<td>No treatment</td>
<td>22</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sim et al</strong>&lt;sup&gt;34&lt;/sup&gt; (Gov, Australia, Novasept)</td>
<td>MMSE 22+, SMC, normal daily functioning</td>
<td>EPA-rich fish oil</td>
<td>Vegetable oil</td>
<td>17</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
Table DS2  Characteristics and validity of studies that do not specify one or two primary efficacy outcomes meeting inclusion criteria for this review, with number of outcomes and significant results (continued)

<table>
<thead>
<tr>
<th>Study (support source)</th>
<th>Inclusion criteria</th>
<th>Treatment group</th>
<th>Control group</th>
<th>Duration</th>
<th>Measures on which control and intervention groups differed significantly; post-intervention mean (s.d.) and statistical comparisons</th>
<th>Validity (answers to questions 1–5 in method)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suzuki et al&lt;sup&gt;42&lt;/sup&gt; (Gov, Japan)</td>
<td>Aged 65+, amnestic MCI&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Multicomponent exercise group 90 min, 2 days/week</td>
<td>Educational group</td>
<td>1 year</td>
<td>MMSE: n/a, WMS-LM I: n/a, Verbal fluency: n/a</td>
<td>LMM: F=3.4, P=0.04; LMM: F=3.9, P=0.03</td>
</tr>
<tr>
<td>Tian et al&lt;sup&gt;27&lt;/sup&gt; (Gov, China)</td>
<td>MCI, SMC, age 45–70, CDR &lt;1; MMSE 25+</td>
<td>Ginseng</td>
<td>Placebo</td>
<td>12 weeks</td>
<td>Cognitive score: 5.3&lt;sup&gt;d&lt;/sup&gt; vs 6.2&lt;sup&gt;d&lt;/sup&gt;; Verbal subscale: 18.6&lt;sup&gt;d&lt;/sup&gt; vs –60&lt;sup&gt;d&lt;/sup&gt;</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>Troyer et al&lt;sup&gt;24,6&lt;/sup&gt;</td>
<td>Amnestic MCI&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10 × 2 h relaxation and memory strategy groups</td>
<td>Wait list</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelton et al&lt;sup&gt;27&lt;/sup&gt; (Gov, USA; Pfizer and Eisai)</td>
<td>Amnestic MCI&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10 × 2 h relaxation and memory strategy groups</td>
<td>Wait list</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhou et al&lt;sup&gt;50&lt;/sup&gt; (Gov, China)</td>
<td>MCI, SMC, MMSE 24–27, aged &lt;80, HRSD &lt;18</td>
<td>Shenyin oral liquid 10 ml bd Vitamin E tablets 500 mg</td>
<td>Placebo</td>
<td>1 year</td>
<td>CDT Picture recognition: 1.25 (1.13) vs 0.26 (1.1)</td>
<td>P&lt;0.001</td>
</tr>
</tbody>
</table>

Gov, national government supported funding source; MCI, mild cognitive impairment; DSST, Digit Symbol Substitution Test; n/a, not available; CDT, Clock Drawing Test; MMSE, Mini-Mental State Examination; AAMI, age-associated memory impairment; CANTAB, Cambridge Automated Neuropsychiatric Test Assessment Battery; ChE, cholinesterase inhibitor; SMC, subjective memory complaint; CDR, Clinical Dementia Rating scale; CVLT, California Verbal Learning Test; GDS, Geriatric Depression Scale; TENS, transcutaneous electrical nerve stimulation; GARS, Groninger Activity Restriction Scale; HRSD, Hamilton Rating Scale for Depression; WMS, Wechsler Memory Scale III; MWU, Mann–Whitney U-test; LG, LG Household & Health Care Ltd; GLDS, Global Deterioration Scale; NPT, neuropsychological testing battery; ADL, activities of daily living; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; MMMS-UIA, Logical Memory subtest of the Wechsler memory Scale-Revised; bd, twice daily.

<sup>a</sup> Diagnosed according to Petersen criteria.
<sup>b</sup> Summary statistics are given by median split of homocysteine levels; high H indicates value for those scoring above this cut-point; low H for those scoring below.
<sup>c</sup> Age-associated memory impairment diagnosed using Crook criteria.
<sup>d</sup> Mean change rather than mean post-intervention displayed.
<sup>e</sup> Charity, Dejardins Financial and Richter Usher & Vineberg.